📰 Recursion Map News
Page 2 - Recursion Map News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recursion Map. Real-time updates on events, politics, business and more.
March 2, 2022
/PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its...
February 8, 2022
/PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its...
February 8, 2022
/PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its...
December 6, 2021
/PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery,...
November 30, 2021
/PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery,...
October 7, 2021
/PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology,...
June 9, 2021
Zavain Dar, Lux Capital Altitude Lab, a healthcare and life sciences incubator founded in 2020 by Recursion and The University of Utahs PIVOT Center, fills the critical role of attracting and supporting underrepresented entrepreneurs. The incubator focuses on developing diverse and inclusive businesses to innovate lower cost, higher quality, and more accessible healthcare solutions. Altitude Labs first cohort includes nine minority or women founders, who are tackling everything from personalize...
May 25, 2021
Share this article Share this article SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurren...
May 12, 2021
/PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological...
April 16, 2021
Recursion Pharmaceuticals Announces Pricing of Initial Public Offering News provided by Share this article Share this article SALT LAKE CITY, April 16, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock. The gross proceeds from the offering, before deducting underwriting di...